Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and ZIJUN XU-MONETTE.
L JEFFREY MEDEIROS
Connection Strength
2.463
ZIJUN XU-MONETTE
  1. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
    View in: PubMed
    Score: 0.170
  2. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321.
    View in: PubMed
    Score: 0.154
  3. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 12 29; 128(26):3083-3100.
    View in: PubMed
    Score: 0.144
  4. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2016 07 15; 22(14):3593-605.
    View in: PubMed
    Score: 0.138
  5. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016 Feb; 8(2):345-65.
    View in: PubMed
    Score: 0.137
  6. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015 Dec; 28(12):1555-73.
    View in: PubMed
    Score: 0.135
  7. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar 20; 6(8):5615-33.
    View in: PubMed
    Score: 0.129
  8. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.118
  9. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40.
    View in: PubMed
    Score: 0.116
  10. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 08; 120(19):3986-96.
    View in: PubMed
    Score: 0.109
  11. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83.
    View in: PubMed
    Score: 0.104
  12. EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588.
    View in: PubMed
    Score: 0.052
  13. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol. 2019; 9:107.
    View in: PubMed
    Score: 0.043
  14. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019 06; 32(6):741-754.
    View in: PubMed
    Score: 0.042
  15. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817.
    View in: PubMed
    Score: 0.041
  16. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018 06; 20(6):574-593.
    View in: PubMed
    Score: 0.040
  17. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716.
    View in: PubMed
    Score: 0.038
  18. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668.
    View in: PubMed
    Score: 0.037
  19. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611.
    View in: PubMed
    Score: 0.036
  20. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017 03; 31(3):625-636.
    View in: PubMed
    Score: 0.036
  21. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
    View in: PubMed
    Score: 0.035
  22. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16.
    View in: PubMed
    Score: 0.034
  23. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.
    View in: PubMed
    Score: 0.034
  24. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
    View in: PubMed
    Score: 0.033
  25. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015 Oct; 28(10):1297-314.
    View in: PubMed
    Score: 0.033
  26. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
    View in: PubMed
    Score: 0.033
  27. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.
    View in: PubMed
    Score: 0.033
  28. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45.
    View in: PubMed
    Score: 0.033
  29. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23.
    View in: PubMed
    Score: 0.031
  30. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol. 2014 Aug; 18(4):203-9.
    View in: PubMed
    Score: 0.030
  31. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.
    View in: PubMed
    Score: 0.030
  32. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.
    View in: PubMed
    Score: 0.030
  33. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014 Jul; 27(7):958-71.
    View in: PubMed
    Score: 0.030
  34. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol. 2013 Dec; 44(12):2658-67.
    View in: PubMed
    Score: 0.029
  35. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016 Feb; 30(2):361-72.
    View in: PubMed
    Score: 0.029
  36. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40.
    View in: PubMed
    Score: 0.028
  37. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250.
    View in: PubMed
    Score: 0.028
  38. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24.
    View in: PubMed
    Score: 0.028
  39. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21.
    View in: PubMed
    Score: 0.027
  40. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98(2):255-63.
    View in: PubMed
    Score: 0.027
  41. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 Sep; 26(9):2103-13.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.